110 results about "Immune adjuvant" patented technology

The invention provides a tumor cell vaccine as well as a preparation method and application thereof. The preparation method comprises the following steps: acquiring and culturing tumor cells; enabling the cell membrane of the tumor cell to express a targeting antibody by utilizing a gene vector infection or gene editing technology, and enabling the targeting antibody to be used for enabling the tumor vaccine to be combined with the dendritic cell; performing overexpression of tumor specific protein on the cell membrane surface of the tumor cell by using a gene vector infection or gene editing technology; a nucleic acid substance of a target protein is wrapped by lipid nanoparticles to form a vaccine framework, and the nucleic acid substance can enable target cells to express directional chemotactic molecules; wherein the directed chemotactic molecule is used for transferring the dendritic cells to lymph nodes; the target vaccine is obtained by wrapping the vaccine framework with the cell membranes of the tumor cells, lymph node homing of the dendritic cells can be promoted, and the antigen presentation efficiency is increased and the immune effect is enhanced through tumor specific protein carried by the target vaccine and assisted by an immunologic adjuvant.

The invention is applicable to the technical field of genetic engineering and biological medicine, and provides a construction method and an expression system of recombinant protein for preventing infectious bronchitis of chicken and application of the recombinant protein. Coding DNA of multi-antigen epitope tandem protein from infectious bronchitis virus N, S1 protein is connected to obtain a fusion recombinant protein IBV: NS1 coding gene, a recombinant expression plasmid pET28a-IBV: NS1 is constructed and transferred into E. coli Rosetta (DE3) competent cells to obtain an E. coli genetic engineering expression bacterium Ec-RD-pET28a-IBV: NS1, and the fusion recombinant protein IBV: NS1 is obtained through induced expression and massive purification. And mixing with an immunologic adjuvant to prepare the subunit vaccine. The subunit vaccine has the advantages of high antigen expression quantity, long antibody maintenance time, high purity, good safety, strong immunogenicity and strong protectiveness, and can effectively prevent infectious bronchitis.

The invention discloses mucosal immune-enhanced recombinant lactobacillus for expressing PEDV (porcine epidemic diarrhea virus) S1 protein as well as a construction method and application of the mucosal immune-enhanced recombinant lactobacillus. The mucosal immune-enhanced recombinant lactobacillus contains a recombinant lactobacillus expression vector for expressing PEDV S1 protein, the amino acid of the PEDV S1 protein is fused with M cell targeting peptide (Co1) and dendritic cell targeting peptide (6aa), the carboxyl terminal of the PEDV S1 protein is fused with a mucosal immune adjuvant (LTB), and the connection sequence of all the parts is Co1-6aa-S1-LTB. According to the mucosal immune enhanced recombinant lactobacillus constructed by the invention, through the synergistic effect of the targeting peptide (DC / MC targeting peptide) and the adjuvant (LTB), the mucosal immune response efficiency (including intestinal mucus SIgA and serum IgG levels) of a PEDV S1 antigen is remarkably improved, humoral immunity, cellular immunity and mucosal immune responses of pregnant animals can be remarkably induced, maternal antibodies are generated, and the immune response efficiency of the pregnant animals is remarkably improved. The intestinal SIgA level of newborn animals is improved, and an effective technical means is provided for prevention and treatment of PED.

The application discloses an oral nano-vaccine and a preparation method and application thereof, and relates to the technical field of immunology, and specifically discloses an oral nano-vaccine which comprises a nano-particle wrapped by a biomimetic bacterial membrane vesicle and an outer layer; the nano-particle comprises an antigen and a biodegradable polymer material; the biomimetic bacterial membrane vesicle comprises an ionizable flagellar lipoprotein, an immune adjuvant, a phospholipid, a sterol lipid and a polyethylene glycol lipid; and the outer layer is a pH-responsive polymer. The oral nano-vaccine provided by the application combines the immune activation advantages of natural bacterial membrane vesicles and the precise regulation characteristics of synthetic materials, significantly improves the transmembrane penetration capacity of the antigen in the intestinal epithelium and the overall activation effect of the mucosal immune system. The oral nano-vaccine provided by the application can protect the antigen and the immune adjuvant from degradation and realize precise release in the intestinal microenvironment; and the oral nano-vaccine significantly improves the bioavailability and safety of an oral tumor vaccine, and lays a key technical foundation for clinical transformation and large-scale production of the oral tumor vaccine.

The present invention provides a glutathione-activated co-assembled nanoprobe and a preparation method and application thereof, belonging to the technical fields of chemical synthesis, biological analysis and detection, tumor imaging and treatment. In the present invention, amphiphilic small molecule probes 1-Zn-PPA and 1-NLG are constructed, and the probes 1-Zn-PPA and 1-NLG can be co-assembled in a solution to form co-assembled nanoprobes 1-NPs. The nanoprobes 1-NPs can accumulate at the tumor site under the tumor EPR effect and the targeting action of cRGD on the probe surface, and disassemble under the action of GSH present in the tumor reducing environment to release Gd-containing hydrophilic small molecule 2-Gd, light / sound-sensitive drug Zn-PPA-SH and immune adjuvant drug NLG919. The nanoprobes 1-NPs can realize combined sonodynamic therapy / photodynamic therapy / immunotherapy of living tumors. The nanoprobes 1-NPs have good applications in fluorescence imaging, magnetic resonance imaging, and the preparation of tumor treatment drugs and tumor-killing devices.

The invention belongs to the technical field of biological medicine, and particularly relates to a nano vaccine based on GD2 mimetic peptide as well as a preparation method and application of the nano vaccine. The nano vaccine provided by the invention comprises a GD2 mimetic peptide, an STING agonist and a polymer carrier, wherein the STING agonist is used as an immunologic adjuvant. The antigen peptide (GD2 mimic peptide 47-LDA) and the adjuvant (STING agonist) are wrapped in the micelle to prepare the nano vaccine GD2-NV, so that the druggability of the antigen peptide and the STING agonist is improved, and the accumulation of drug tumors and drainage lymph node parts is improved. Besides, the nano vaccine can respond to a lysosome acid environment, realize lysosome escape, enhance antigen cross presentation of DC, activate an STING pathway, improve infiltration and activation degrees of CD8 + T cells, induce lasting humoral immune response and inhibit growth and recurrence of tumors, and is good in biological safety.

This invention discloses a lipid nanoparticle co-delivery system based on phenolic hydroxyl lipids and a manganese adjuvant. Addressing the shortcomings of traditional HPV therapeutic peptide vaccines—weak immunogenicity, easy degradation and inactivation in vivo, low bioavailability of manganese ion adjuvants making spatiotemporal co-delivery with antigens, and poor encapsulation efficiency and insufficient biosafety of conventional lipid nanocarriers—this invention constructs an integrated nanovaccine delivery system by embedding phenolic hydroxyl functional lipids into a nanocarrier framework, synergistically loading HPV E6 / E7 specific antigen peptides and manganese ion immune adjuvants. This system achieves efficient delivery, immune activation, and anti-tumor efficacy, integrating the functions of efficient antigen delivery, potent immune activation, and precise anti-tumor action. The preparation process is simple and exhibits excellent stability, overcoming the limitations of traditional HPV peptide vaccines with poor efficacy when used alone. It has broad research value and clinical translation prospects in the field of precision immunotherapy for HPV-related cervical cancer, head and neck squamous cell carcinoma, and other malignant tumors.

The present application relates to rainbow trout nucleic acid vaccine adjuvant, the adjuvant includes polydisulfide compound and cyclic di-GMP delivered by polydisulfide compound, the present application also relates to the application of the rainbow trout nucleic acid vaccine adjuvant in the preparation of rainbow trout IHNV virus nucleic acid vaccine.A kind of rainbow trout nucleic acid vaccine adjuvant, i.e.c-di-GMP+CPD complex, is developed based on STING agonist-c-di-GMP and polydisulfide compound (CPD) delivery carrier, so as to realize the cost reduction and efficiency increase of rainbow trout nucleic acid vaccine, polydisulfide compound (CPD) can efficiently deliver cyclic di-GMP, and have good stability, c-di-GMP+CPD complex has the potential as rainbow trout immune adjuvant, can significantly enhance the immune protection effect of rainbow trout nucleic acid vaccine, reduces vaccine dosage.

This invention discloses a genetically engineered bacterium capable of synthesizing large quantities of natural cyclic diguanylate (c-di-GMP) and its applications. It involves knocking out the major phosphodiesterase gene chr1_233 as described in claim 1 within the sphingobium xenophagum C2 strain. This invention rationally designs and modifies the c-di-GMP synthesis and degradation pathways and the inhibitory site of major diguanylate cyclase activity in heterologous sphingobium-consuming bacteria, constructing a series of genetically engineered bacteria capable of synthesizing large quantities of natural c-di-GMP. This provides the industry with a green, simple, economical, and efficient method for producing natural c-di-GMP, and offers a series of high-quality and inexpensive raw materials for the preparation of STING agonists or immune adjuvants, or for the preparation of drugs for treating diseases related to STING protein function.

The invention discloses a bovine I-type tau interferon-ferritin fusion protein as well as a mutant and application thereof. The bovine I-type tau interferon is fused with a ferritin subunit, and interferon molecules are highly repeatedly and orderly displayed on the surface of a ferritin nanocage by utilizing the self-assembly characteristic of ferritin, so that a conformation suitable for the ferritin nanocage to play functions is formed, and the expression level, the structural stability and the antiviral activity of the tau interferon are remarkably improved. The fusion protein is subjected to rational design mutation to obtain a single-site or multi-site mutant with significantly improved antiviral activity and stability. According to the invention, a silkworm or insect cell eukaryotic expression system is adopted to express the fusion protein or the mutant thereof, and the expression system is safe to operate, simple and convenient in procedure, low in cost and extremely beneficial to large-scale industrial production; the prepared fusion protein or mutant nanoparticles can be applied to preparation of a plurality of drugs for preventing or treating bovine viral infection, tumors and immune system diseases and immunologic adjuvants for vaccine compatibility.

The present invention provides an RNA-based tumor vaccine, a preparation method, an immune adjuvant, a vector and an application. The tumor vaccine can specifically act on tumors with positive expression of GPC3, such as hepatocellular carcinoma, ovarian clear cell carcinoma, yolk sac carcinoma, etc. The tumor vaccine includes circular RNA capable of encoding an immunogenic polypeptide. The circular RNA is configured to be capable of specifically encoding the immunogenic polypeptide GPC3. The circ-GPC3 in the present invention has a covalently closed-loop structure that can protect it from exonuclease-mediated degradation, has a longer half-life and higher stability compared to mRNA, and can ensure the continuous expression of immunogenic proteins. By artificially modifying and introducing a ribosome entry site (IRES) modification, the present invention can increase the translation efficiency of tumor-specific antigen RNA.

The invention relates to the technical field of biology, in particular to a cat triple vaccine immunologic adjuvant containing three cat interleukinins and manganese ions, a composition and application. The composition comprises feline interleukin 2, feline interleukin 4, feline interleukin 6 and manganese ions, and can be used for preparing a feline triple vaccine or an immune preparation of the feline triple vaccine, and the feline triple vaccine immune adjuvant containing the three feline interleukin comprises the compound. The immunologic adjuvant disclosed by the invention has the characteristics of safety and high efficiency, not only can effectively solve the limitation of the existing vaccine, but also can further enhance the comprehensive protective efficacy of the cat triple vaccine on the three viruses, is long in immunization duration, effectively reduces adverse reactions, remarkably improves the safety and protection rate of inoculation, and has a good application prospect. The method is of great significance to promotion of feline disease prevention and pet health management.

The invention discloses a novel benzothiazole compound as well as a preparation method and application thereof. According to the novel benzothiazole compound, through targeted activation of an RIG-I / OAS innate immune pathway, expression of key proteins and genes such as OAS1 and RIG-I can be rapidly up-regulated, secretion of type I interferon and proinflammatory factors is induced, and instant immune enhancement is achieved; more importantly, by performing long-term functional reprogramming on innate immune cells (such as mononuclear cells and dendritic cells), persistent'innate immune memory '(namely immune domestication) can be induced. The dual-action mechanism can significantly enhance the activation of antigen presenting cells and promote the generation and long-term maintenance of memory B cells and effector memory T cells, has no significant toxicity to liver functions, can be used as an immunologic adjuvant and an immunodomestication molecule of an RSV vaccine, can synergistically improve the vaccine-induced RSV specific antibody titer and neutralizing antibody level, and can be used for preparing an immunologic adjuvant for the RSV vaccine. Long-acting immune protection is provided, and a brand new solution is provided for research and development of RSV vaccines.

The invention discloses a multilayer nanofiber oral paste loaded with an allergen-immunologic adjuvant composition as well as a preparation method and application of the multilayer nanofiber oral paste. The multilayer nanofiber oral paste has an adhesion function. The multilayer nanofiber oral paste is prepared by adopting a continuous electrostatic spinning technology, the adhesion layer is prepared from a polymer material, and the backing layer is prepared from a hydrophobic polymer material. The invention relates to an allergen-immunologic adjuvant composition, and the allergen-immunologic adjuvant composition or a composition nanoparticle is loaded by an adhesive layer. The multi-layer nanofiber oral paste is applied to an oral mucosa area of a patient within a treatment course, so that long-acting release of allergens is realized. After the multi-layer nanofiber oral paste is repeatedly used by a patient, the prevention or treatment of allergic diseases (allergic diseases) can be realized.

The invention discloses an engineered adoptive macrophage based on a nano battery as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The preparation method disclosed by the invention comprises the following steps: taking an immunologic adjuvant working solution as a raw material, and obtaining nanoparticles with high drug loading capacity through an assembly effect; as the main energy of ChARM comes from an immunologic adjuvant, the high-drug-loading nano-particle is also called a high-energy-density nano-battery. Diluting the obtained nano particles with a cell culture medium, and co-incubating the diluted nano particles and macrophages to obtain engineered macrophages loaded with the anti-tumor or anti-inflammatory nano battery; the assembly mode is any one of supramolecular assembly, prodrug assembly or metal coordination assembly; the high-density drug-loaded nano battery can endow engineered cells with excellent biological functions. The method solves the technical problems that the preparation of the existing CAR-M is expensive, the gene modification is complex, and the nano-drug delivery system is unstable.

The invention relates to the technical field of medicines, in particular to a zinc ion polypeptide compound immunologic adjuvant as well as a preparation method and application thereof. The preparation method comprises the following steps: mixing polypeptide, a PBS buffer solution, new coronavirus S protein, a CpG ODN immune activator and zinc ions, and standing to obtain the zinc ion polypeptide compound immunologic adjuvant. A dual-adjuvant system mixed with CpG ODN shows excellent performance in activation of lung tissue immunity, and in the cellular immunity level, the response intensity of CD4 + T and CD8 + T cells is enhanced, and formation of related tissue resident memory T cell phenotypes is promoted; on the humoral immunity level, a Gel (Zn < 2 + >) and CpG ODN dual-adjuvant system obviously stimulates the increase of the number of B cells and the activation, and can effectively stimulate the secretion of a main antibody sIgA for mucosal immunity. On the whole, the dual adjuvants realize the synergistic enhancement of T cell (containing TRM) and B cell immunity.

A method for preparing aluminum hydroxide dry powder and its sol, and its application, relates to the field of vaccine adjuvant preparation. The method includes: preparing an ammonia solution or sodium hydroxide solution; preparing an aluminum chloride solution; neutralizing the ammonia solution or sodium hydroxide solution with the aluminum chloride solution at 15-20°C to generate a milky white, translucent colloidal suspension; filtering; freeze-drying followed by aging to obtain aluminum hydroxide dry powder; adding the dry powder to a sodium chloride electrolyte solution, processing it in a high-speed shear disperser, redispersing the dry powder into a sol at a certain temperature, and homogenizing it cyclically in a high-pressure homogenizer to obtain aluminum hydroxide sol; removing electrolytes from the aluminum hydroxide sol using electrodialysis, followed by high-pressure sterilization and packaging. This invention solves the problems of clumping and sedimentation during sterilization and storage, poor stability, inconvenience in transportation and use, and limited concentration in existing aluminum hydroxide adjuvant preparation methods.

The present invention provides a method for detecting quality differences in immune adjuvants, comprising: establishing a standard curve of the logarithmic values ​​of CT and C based on the CT value and the logarithmic value of C of a qPCR reaction of a standard plasmid containing a quality control fragment of the target immune adjuvant; substituting the CT value of the qPCR reaction of target immune adjuvants from different production batches into the standard curve to obtain the logarithmic values ​​of C of the target immune adjuvants from different production batches; comparing the logarithmic values ​​of C or C of the target immune adjuvants from different production batches to obtain a comparison result; and obtaining the quality differences of the target immune adjuvants from different production batches based on the comparison result. The present invention utilizes qPCR technology to perform quality control on the immunologically active motif of the target immune adjuvant, and provides a method for detecting quality differences of target immune adjuvants from different production batches. Compared with quality control studies using unmethylated CpG, the present invention eliminates the need for complex operations such as sample methylation treatment and high-performance liquid chromatography.

Cancer treatment using ultra-high concentration gaseous nitric oxide (UNO) and a checkpoint inhibitor and, optionally, an immune adjuvant is provided. Additionally, UNO as a sensitizing treatment to checkpoint inhibitors is provided. Accordingly, there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of UNO and a checkpoint inhibitor and, optionally, an immune adjuvant.

The present invention discloses a nanoparticle adjuvant co-loaded with anionic and hydrophobic immune adjuvants and its application. The nanoparticle adjuvant comprises ionizable lipids, anionic immune adjuvants and / or hydrophobic immune adjuvants and auxiliary lipids, and the auxiliary lipids include neutral auxiliary lipids, cholesterol and pegylated lipids. The present invention uses ionizable lipid materials to encapsulate anionic adjuvants and hydrophobic adjuvants with different functions to prepare a new nanoparticle adjuvant system. The nanoparticle adjuvant system breaks through the limitations of traditional reliance on cationic lipids to load anionic adjuvants and hydrophobic adjuvants; at the same time, the nanoparticle adjuvant immune adjuvant prepared by the present invention has a high encapsulation rate. After being applied to animals, it can produce strong humoral immunity and significantly enhance cellular immunity. The immune effect is better than free antigen / adjuvant mixed injection and existing aluminum adjuvant-containing vaccines and other VZV vaccines currently available on the market.

Disclosed are a composition and method of treating some HPV-related solid tumors in mammalian subjects. In one embodiment, a method comprises delivering a self-assembling vaccine intradermally to a subject. In at least one embodiment, the self-assembling vaccine comprises a fusion protein non-covalently attached to two or more biotinylated E6 / E7 peptides, derived from targeted viral or oncogenic protein epitopes, using a biotin-avidin engagement.

The application specifically discloses a kind of nanovaccine for thrombosis prevention and its preparation method and application, it is related to thrombotic disease, especially related to the nanovaccine for treating thrombotic disease.The nanovaccine provided by the application has good immunogenicity without macromolecular heterologous protein carrier such as KLH;The process simplicity and repeatability are improved by reducing complex chemical coupling and purification steps;The dependence on traditional high-stimulating immune adjuvant is reduced, and the biological safety is improved;The stability of antigen in gastrointestinal environment is significantly improved;Active targeting delivery of M cells and dendritic cells is realized;Dendritic cell maturation and antigen presentation are promoted, and mucosal immunity and systemic immunity level are improved;The advantages such as effectively inhibiting thrombosis are realized, and a new type of oral antithrombotic vaccine system with high compliance suitable for long-term thrombosis prevention is constructed.

A platform of drug delivery based on self-lysis of ECN, a constructing method, and use of the platform are provided. The platform of drug delivery comprises ECN, a Pvhb-GST-PhiX174E circuit genetically introduced into ECN, and a drug encapsulation material. When the platform is used as an anti-cancer drug carrier, the platform delivers a high concentration of chemotherapeutic drugs to a tumor site. Additionally, through the Pvhb-GST-PhiX174E circuit, ECN is induced to lyse in response to tumor microenvironment signals, leading to cell death in the tumor region and enhancing ECN's biosafety in vivo. Furthermore, ECN within the platform of drug delivery based on self-lysis of ECN serves as an immune adjuvant, stimulates the immune cell activity in the tumor site, triggers acute inflammation, and strengthens the anti-tumor effect, thereby achieving multi-modal anti-tumor therapy through live-cell, chemotherapy, and immunotherapy.

The present invention belongs to the technical field of veterinary biological products, and specifically relates to the application of a polypeptide in the preparation of a Newcastle disease vaccine adjuvant or an immune potentiator product. The amino acid sequence of the polypeptide is as follows: NPEVILPVPAFNVINGGSH. When chickens are immunized with a live Newcastle disease vaccine by injection, and simultaneously orally or subcutaneously injected with the NH-19 polypeptide, the immune effect of the Newcastle disease vaccine can be improved, and it can be used as an immune adjuvant or an immune potentiator. After vaccination, good specific antibodies are produced. On the 3rd, 7th, and 14th days after immunization, the NDV HI antibody levels in the polypeptide group are higher than those in the healthy control group and the vaccine control group, indicating that the polypeptide improves the immune effect of the live NDV vaccine.

The application provides a double-strand DNA vaccine for late Edwardsiella tarda disease, which can significantly induce Th1 type immune bias, enhance fish cell immune response, improve the resistance to intracellular bacterial infection, and has the advantages of safety and high efficiency, easy preparation, strong adaptability for on-site promotion and the like. The double-strand DNA vaccine uses a fusion fragment of an immune adjuvant IL-12, which is constructed by connecting a nucleic acid fragment coding a subunit 12p35 with an amino acid sequence of SEQ ID NO:1 and a nucleic acid fragment coding a subunit 12p40 with an amino acid sequence of SEQ ID NO:3 through a flexible connecting peptide linker. The double-strand DNA vaccine realizes the synergistic expression of OmpC antigen and IL-12 adjuvant, enhances immunogenicity, and solves the problem of insufficient immune effect of a traditional DNA vaccine; and the vaccine has no obvious toxic side effect on fish bodies, is not dependent on the use of antibiotics, is green and environmentally friendly, and has a good industrialization prospect.

The application provides an mRNA vaccine and a preparation method and application thereof. Specifically, the application provides application of GMCSF as an immune adjuvant in preparation of an mRNA vaccine, and further provides an mRNA molecule, which encodes a GMCSF-antigen-FC1 fusion protein, wherein the GMCSF-antigen-FC1 fusion protein comprises, from an N terminus to a C terminus, an amino acid sequence of GMCSF, an amino acid sequence of an antigen and an amino acid sequence of FC1 in sequence, wherein the antigen is an antigen from a virus. The mRNA molecule of the application can be used for preparing a vaccine for preventing infection of novel coronavirus BA2 and BA5 mutant strains, and can induce a strong immune response.

The present application belongs to the field of biomedical technology, and more particularly relates to the application of Periplaneta americana polypeptide HFDT1 as an immune adjuvant in the preparation of a brucellosis vaccine. The present application uses Brucella OMP10, BP26 and L7 / L12 proteins in combination with HFDT1 to induce mice to produce higher titers of anti-OMP10, BP26 and L7 / L12 protein specific IgG antibodies, and the titers increase with the increase in the number of immunizations, while promoting the body to produce mixed Th1 / Th2 type cellular immune responses and stimulating the proliferation and differentiation of mouse spleen T and B cells, and also facilitating mass production. The Periplaneta americana polypeptide HFDT1 described in the present application is obtained by convenient mass synthesis, and can be used as a novel small molecule immune adjuvant to enhance specific immune responses of the body.

The application belongs to the field of marine biotechnology, and particularly relates to natural polysaccharide-quaternized chitosan nanoparticles with immune stimulation and preparation and application thereof. The nanoparticles formed by natural polysaccharide with negative charge and quaternized chitosan with positive charge are obtained by polyelectrolyte complexation, the particle size is 316.4 nm, and the potential is 31.1 mV; the quaternized chitosan with positive charge and the natural polysaccharide with negative charge are mixed in a mass ratio of 6.25-10:1-4. After immunization of mice, the secretion amount of immunoglobulin IgG and immune factors in the mice is determined, which shows that the nanoparticles have good immune activity, thereby playing an effect in vaccine adjuvant. The application provides a method and guidance for the research on natural polysaccharide and chitosan derivatives as immune adjuvants in recent years.

The present invention discloses the application of atorvastatin calcium in the preparation of an anti-tumor preparation for enhancing dendritic cell vaccines, belonging to the technical field of immune adjuvants. The application of atorvastatin calcium disclosed by the present invention in the preparation of an anti-tumor preparation for enhancing dendritic cell vaccines. Atorvastatin calcium can be used in the preparation of dendritic cell vaccines, significantly up-regulating the expression of pro-inflammatory factors Tnfa, Il6, Il12p40, and Il12p35 and the expression of surface co-stimulatory molecules CD80 and CD86 in dendritic cells, promoting the ability of dendritic cells to mediate the activation of CD4+ T cells and CD8+ T cells and their differentiation into IFNγ-secreting effector cells, and effectively enhancing the anti-tumor effect of dendritic cell vaccines. The present invention provides a method for using atorvastatin calcium in the preparation of dendritic cell vaccines to promote the efficacy of dendritic cell vaccines, providing a new direction for tumor prevention and treatment.

The application discloses a mucosal immunity enhanced recombinant lactobacillus expressing PEDV S1 protein and a construction method and application thereof. The mucosal immunity enhanced recombinant lactobacillus contains a recombinant lactic acid bacteria expression vector expressing the PEDV S1 protein, wherein the PEDV S1 protein is fused with an M cell targeting peptide (Col) and a dendritic cell targeting peptide (6aa) at an amino acid end, and is fused with a mucosal immunity adjuvant (LTB) at a carboxyl end; and the connection sequence of each part is Col-6aa-S1-LTB. The mucosal immunity enhanced recombinant lactobacillus constructed by the application significantly improves the mucosal immunity response efficiency (including intestinal mucus SIgA and serum IgG levels) of the PEDV S1 antigen through the synergistic effect of the targeting peptide (DC / MC targeting peptide) and the adjuvant (LTB), and can significantly induce humoral immunity, cellular immunity and mucosal immunity response of pregnant animals and produce maternal antibodies, improves the intestinal SIgA level of newborn animals, and provides an effective technical means for the prevention and treatment of PED.